Manufacturers report positive results for olanzapine and samidorphan combination (Lybalvi®) in phase 3b study of patients with schizophrenia
In the ENLIGHTEN-Early study (n=428, age 16 to 39 years), patients receiving olanzapine in combination with this opioid-mu receptor antagonist, experienced less weight gain vs those on olanzapine alone by week 12 (4.91% vs. 6.77% increase in weight, respectively, p=0.012).
Source:
Biospace Inc.
SPS commentary:
Lybalvi is licensed in the US for schizophrenia and bipolar disorder, but a marketing authorisation application has not yet been filed for use in the UK.